Back to today’s briefing

Story perspectives

New Treatment Boosts Multiple Myeloma Survival Rates by 59%

6/4/2025

50 6

Summary

Daratumumab Boosts Outcomes

In a groundbreaking advancement for multiple myeloma treatment, the ADVANCE trial revealed that incorporating daratumumab into the standard KRd regimen dramatically boosts patient outcomes. With an impressive 59% achieving minimal residual disease negativity compared to just 36% with KRd alone, this combination sets a new benchmark in patient care and hope for those newly diagnosed.

Summary

Memorial Sloan Kettering Advances

At the 2025 ASCO Annual Meeting, Memorial Sloan Kettering Cancer Center unveiled groundbreaking cancer treatment advancements. The MATTERHORN trial highlighted durvalumab's potential to boost event-free survival in gastric cancer, while the NeoADAURA trial showcased improved responses in EGFR-mutated lung cancer. These promising results signal a transformative shift towards tailored therapies that could change lives.

1 of 2

Daratumumab Boosts Outcomes

In a groundbreaking advancement for multiple myeloma treatment, the ADVANCE trial revealed that incorporating daratumumab into the standard KRd regimen dramatically boosts patient outcomes. With an impressive 59% achieving minimal residual disease negativity compared to just 36% with KRd alone, this combination sets a new benchmark in patient care and hope for those newly diagnosed.

1 / 2